BLOOMFIELD HILLS, MI--(Marketwired - Jun 17, 2013) - Michigan-based natural products developer Health Enhancement Products (
The application was prompted by recent genetic tests that revealed certain signaling pathways and gene activation utilizing RNA from an ongoing bovine mastitis study conducted by Dr. Laura Hernandez, a lactation expert and faculty member at the University of Wisconsin-Madison. Dr. Hernandez has been working in vitro with isolated samples of the Company's proprietary bioactive compounds and their effects on primary bovine mammary epithelial cells exposed to inflammatory and infective agents.
In addition, the Company awarded a unit of Covance, a US-based contract research organization, a contract to validate beneficial osteoarthritis efficacy in a canine model, to include in vitro and ex vivo experiments. Preliminary results are expected in the next few weeks. Both studies are being managed by the Company's new director of research & development, Dr. Amy E. Steffek, who joined the firm several weeks ago.
These most recent test results also prompted a request by the Company's CEO to the University of Wisconsin to assess the viability of a urine-based bovine stress and metabolic test. The purpose of the test is to profile animals susceptible to stress-induced conditions that may then progress into infectious diseases or autoimmune disorders. The provisional patent application for such a test was filed on Friday, June 14 by Kohn and Associates, Inc., a patent law firm based in Michigan.
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
